Amgen Prolia Sales Fall 45% to $632 Million in Q3
Prolia sales fell from $1.139 billion a year earlier; Amgen said 23% lower volume accounted for part of the decline, with biosimilars eroding its market position.
Amgen's osteoporosis drug Prolia saw third-quarter sales fall to $632 million, a 45% decline from $1.139 billion a year earlier. Multiple biosimilars have launched globally, eroding Prolia's market position. The company said 23% lower volume accounted for part of the decline, with the remainder spl…